Date: 2011-03-16
Type of information: Production agreement
Compound: MOR208 ( anti-CD19 monoclonal antibody)
Company: MorphoSys (Germany) Boehringer Ingelheim (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism:
Disease: chronic lymphocytic leukemia and potentially other B-cell malignancies
Details: MorphoSys AG and Boehringer Ingelheim have signed a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys\'s proprietary MOR208 program and other drug candidates. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys\'s partner Xencor Inc.
Financial terms:
Latest news:
